Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PITX2 adjacent non-coding RNA (PANCR) is a long intergenic non-coding RNA (lncRNA) discovered adjacent to the PITX2 gene at the chromosome 4q25 locus[1][4]. PANCR is specifically expressed in the left atrium and eye, and not in other heart chambers[1][4]. It is co-expressed with PITX2c, a key isoform of the PITX2 transcription factor involved in cardiac development, and its levels are tightly correlated with those of PITX2c[1][4]. PANCR knockdown reduces PITX2c expression in differentiating cardiomyocytes, influencing the transcriptome similarly to direct knockdown of PITX2c, suggesting PANCR acts as a regulatory RNA controlling PITX2c expression, possibly by stabilizing its mRNA in the cytoplasm[1][4]. Observational studies associate variation at the PANCR/PITX2 locus with risk for atrial fibrillation, but PANCR itself is not currently a direct therapeutic target nor does it have known specific drug interactions or safety concerns[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PITX2 adjacent non-coding RNA (PANCR).